{"id":"steroid-drug","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Cushingoid features (with chronic use)"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Insomnia and mood changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Steroids (corticosteroids) work by entering cells and binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators such as cytokines, chemokines, and adhesion molecules. The result is broad immunosuppression and anti-inflammatory effects across multiple organ systems.","oneSentence":"Steroids suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:51.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus)"},{"name":"Allergic reactions and asthma"},{"name":"Adrenal insufficiency"},{"name":"Certain malignancies (as adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT07223671","phase":"PHASE1","title":"Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-31","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT06925737","phase":"PHASE3","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":1440},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT07496060","phase":"PHASE4","title":"Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2025-08-10","conditions":"Anterior Chamber Granulomatous Uveitis","enrollment":66},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT07495007","phase":"PHASE1","title":"An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection","status":"COMPLETED","sponsor":"Zi Diligence Biocenter","startDate":"2025-11-10","conditions":"Bioequivalance, Post-menopause","enrollment":26},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT05954962","phase":"PHASE4","title":"Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.","status":"COMPLETED","sponsor":"Instituto Bernabeu","startDate":"2023-12-23","conditions":"IVF","enrollment":150},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT06899061","phase":"PHASE1","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":"Advanced Solid Malignancies","enrollment":41},{"nctId":"NCT07498140","phase":"NA","title":"Procedural Framing and Epidural Steroid Injection Outcomes","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2026-03-25","conditions":"Lumbosacral Radiculopathy","enrollment":210},{"nctId":"NCT05538897","phase":"PHASE1, PHASE2","title":"Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-31","conditions":"FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma","enrollment":96},{"nctId":"NCT06783621","phase":"PHASE4","title":"A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-01-16","conditions":"Facial Contouring","enrollment":130},{"nctId":"NCT07489521","phase":"PHASE4","title":"Arthrosemid vs. Steroid for the Management Knee Osteoarthritis","status":"RECRUITING","sponsor":"Cappagh National Orthopaedic Hospital","startDate":"2026-03","conditions":"Osteo Arthritis Knee, Osteoarthritis, Intraarticular Injection","enrollment":200},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT04751175","phase":"PHASE4","title":"Management of Pain in Lumbar Arthrodesis","status":"COMPLETED","sponsor":"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","startDate":"2013-07-04","conditions":"Pain, Postoperative","enrollment":128},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT06726148","phase":"PHASE1, PHASE2","title":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-03","conditions":"Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors","enrollment":280},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT03436654","phase":"PHASE2","title":"Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-21","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT04886999","phase":"PHASE3","title":"Study in Adult Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-24","conditions":"Asthma","enrollment":78},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT07496294","phase":"NA","title":"Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy","status":"NOT_YET_RECRUITING","sponsor":"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","startDate":"2026-04","conditions":"Menopausal Women, Menopausal Symptom Relief, Hormone Therapy","enrollment":200},{"nctId":"NCT06998407","phase":"PHASE1, PHASE2","title":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2025-08-20","conditions":"HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":380},{"nctId":"NCT07412470","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-03-13","conditions":"Kidney Transplant Rejection","enrollment":526},{"nctId":"NCT07409779","phase":"NA","title":"Capsular Distension Versus Corticosteroid Injection in Adhesive Capsulitis","status":"NOT_YET_RECRUITING","sponsor":"Faculty of Medicine of Tunis","startDate":"2026-04-01","conditions":"Adhesive Capsulitis of the Shoulder","enrollment":50},{"nctId":"NCT04756726","phase":"PHASE1","title":"Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"C4 Therapeutics, Inc.","startDate":"2021-04-27","conditions":"Multiple Myeloma, Lymphoma, Non-Hodgkin's","enrollment":224},{"nctId":"NCT06232044","phase":"PHASE1, PHASE2","title":"Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-04-23","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":88},{"nctId":"NCT06365853","phase":"PHASE2","title":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-29","conditions":"Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive","enrollment":100},{"nctId":"NCT05845125","phase":"PHASE4","title":"Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone","status":"TERMINATED","sponsor":"Claire Bourgeois","startDate":"2023-05-21","conditions":"Shoulder Pain","enrollment":50},{"nctId":"NCT07492888","phase":"PHASE2","title":"Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04-15","conditions":"Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis","enrollment":20},{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms","enrollment":1314},{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT04149210","phase":"PHASE3","title":"FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2021-08-19","conditions":"Trachomatous Trichiasis (TT), Eye Diseases, Eyelid Diseases","enrollment":2410},{"nctId":"NCT06353386","phase":"PHASE1, PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":220},{"nctId":"NCT02870738","phase":"PHASE2","title":"Bladder Directed vs. Pelvic Floor Therapy in IC/BPS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corewell Health East","startDate":"2017-04-21","conditions":"Cystitis, Interstitial, Painful Bladder Syndrome","enrollment":128},{"nctId":"NCT04563923","phase":"PHASE2","title":"Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2020-10-10","conditions":"Bullous Pemphigoid","enrollment":15},{"nctId":"NCT06235567","phase":"PHASE1, PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":"Keratoconus","enrollment":20},{"nctId":"NCT03926299","phase":"NA","title":"Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Prof. Dr. Volker Viereck","startDate":"2019-07-15","conditions":"Chronic Skin Disease, Vulvar Lichen Sclerosus","enrollment":66},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":"Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer","enrollment":50},{"nctId":"NCT05467891","phase":"PHASE2","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Oana Danciu","startDate":"2022-09-13","conditions":"Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT04799275","phase":"PHASE2, PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":422},{"nctId":"NCT07255248","phase":"PHASE4","title":"Hoffa's Fat Pad Impingement (HFPI)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-03-01","conditions":"Hoffa's Fat Pad Impingement","enrollment":62},{"nctId":"NCT04641351","phase":"PHASE4","title":"Corticosteroid Meniscectomy Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2021-05-27","conditions":"Osteoarthritis, Knee, Meniscus Tear, Meniscus; Degeneration","enrollment":150},{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Multiple Myeloma","enrollment":492},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Prostate Cancer Metastatic","enrollment":1310},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT04576455","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-27","conditions":"Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","enrollment":303},{"nctId":"NCT07136922","phase":"PHASE1","title":"First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency","status":"NOT_YET_RECRUITING","sponsor":"Calla Lily Clinical Care Ltd","startDate":"2026-04","conditions":"Luteal Phase Insuffiency, Progesterone Delivery","enrollment":20},{"nctId":"NCT06563245","phase":"PHASE2, PHASE3","title":"Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2024-09-25","conditions":"Classical Hodgkin Lymphoma, Child, Adolescent","enrollment":96},{"nctId":"NCT05970731","phase":"PHASE2","title":"Directed Topical Drug Delivery for Treatment for PASC Hyposmia","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-09-05","conditions":"Post Acute Sequelae Covid-19 Hyposmia","enrollment":16},{"nctId":"NCT04675788","phase":"PHASE4","title":"Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening","status":"COMPLETED","sponsor":"Indiana University","startDate":"2021-09-02","conditions":"Long QT Syndrome, Abnormalities, Drug-Induced","enrollment":73},{"nctId":"NCT04910568","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-07-26","conditions":"Multiple Myeloma","enrollment":126},{"nctId":"NCT05489211","phase":"PHASE2","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-06","conditions":"Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":454},{"nctId":"NCT06136598","phase":"PHASE1","title":"A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-30","conditions":"Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer","enrollment":14},{"nctId":"NCT06678685","phase":"PHASE2, PHASE3","title":"Spironolactone Improved Children With Gene Mutations Related to NCOR","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-10-30","conditions":"NCOR Gene Mutations, Spironolactone, ASD","enrollment":2},{"nctId":"NCT07482891","phase":"PHASE4","title":"An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2026-03-10","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":200},{"nctId":"NCT07269327","phase":"PHASE1","title":"An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2025-11-24","conditions":"Fertility","enrollment":24},{"nctId":"NCT03173092","phase":"PHASE4","title":"A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2017-11-13","conditions":"Multiple Myeloma","enrollment":141},{"nctId":"NCT06892197","phase":"PHASE4","title":"Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)","status":"RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2026-03-10","conditions":"Community Acquired Pneumonia (CAP)","enrollment":1600},{"nctId":"NCT05654623","phase":"PHASE3","title":"A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-03-03","conditions":"Advanced Breast Cancer","enrollment":624},{"nctId":"NCT07480681","phase":"PHASE1","title":"Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-03","conditions":"Advanced/Metastatic Solid Tumors","enrollment":138},{"nctId":"NCT07222267","phase":"PHASE1","title":"An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-12-11","conditions":"Breast Cancer, Advanced Solid Tumor","enrollment":86},{"nctId":"NCT06892210","phase":"PHASE4","title":"Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)","status":"RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2026-03-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2000},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05272826","phase":"PHASE2","title":"Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients","status":"RECRUITING","sponsor":"Canadian Myeloma Research Group","startDate":"2024-12-12","conditions":"Multiple Myeloma","enrollment":75},{"nctId":"NCT06207123","phase":"PHASE1, PHASE2","title":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-13","conditions":"Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":15},{"nctId":"NCT07476183","phase":"PHASE1","title":"Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia","status":"NOT_YET_RECRUITING","sponsor":"Apriligen, Inc.","startDate":"2026-03","conditions":"RPS19 Deficient Diamond-Blackfan Anemia","enrollment":4},{"nctId":"NCT07038369","phase":"PHASE1","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atavistik Bio, Inc","startDate":"2025-07-29","conditions":"Advanced Solid Tumors, Breast Cancer, Breast Carcinoma","enrollment":134},{"nctId":"NCT05309590","phase":"","title":"Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2014-05","conditions":"Eosinophilic Esophagitis","enrollment":50},{"nctId":"NCT07478003","phase":"PHASE3","title":"Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial","status":"NOT_YET_RECRUITING","sponsor":"Thomas Engstrom","startDate":"2026-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":5204},{"nctId":"NCT06471257","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-17","conditions":"Asthma","enrollment":790},{"nctId":"NCT07473895","phase":"PHASE2","title":"Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06993844","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ensem Therapeutics","startDate":"2025-06-10","conditions":"Advanced Solid Tumors, Advanced Breast Cancer","enrollment":233},{"nctId":"NCT07241585","phase":"NA","title":"Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-05-01","conditions":"Nonmelanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma","enrollment":54},{"nctId":"NCT07287397","phase":"PHASE1, PHASE2","title":"Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS","status":"RECRUITING","sponsor":"Vector Y Therapeutics","startDate":"2025-12-19","conditions":"Amyotrophic Lateral Sclerosis","enrollment":12},{"nctId":"NCT04512235","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-11-03","conditions":"AL Amyloidosis","enrollment":281},{"nctId":"NCT04504825","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-08-25","conditions":"AL Amyloidosis","enrollment":125},{"nctId":"NCT07475663","phase":"PHASE3","title":"Counterpain PXM Versus Diclofenac Versus Piroxicam","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Indonesia","startDate":"2025-11-04","conditions":"Ankle Sprain, Back Pain, Osteoarthritis (OA) of the Knee","enrollment":180},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":"Ductal Carcinoma in Situ","enrollment":400},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT05230810","phase":"PHASE1, PHASE2","title":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Criterium, Inc.","startDate":"2022-08-25","conditions":"HER2-positive Metastatic Breast Cancer","enrollment":40},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT07327931","phase":"NA","title":"PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2026-02-13","conditions":"Hip Osteoarthritis, Hip Pain Chronic","enrollment":120},{"nctId":"NCT05198791","phase":"PHASE2","title":"Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.","status":"RECRUITING","sponsor":"NHS National Waiting Times Centre Board","startDate":"2022-02-04","conditions":"Myocardial Infarction, Acute, Myocardial Infarction With Nonobstructive Coronary Arteries, Myocardial Injury","enrollment":400},{"nctId":"NCT07426458","phase":"PHASE4","title":"Ventilation and Perfusion in Asthmatics","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-04","conditions":"Asthma","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DECREASED APPETITE"},{"count":1,"reaction":"DISEASE PROGRESSION"},{"count":1,"reaction":"NAUSEA"},{"count":1,"reaction":"NEUTROPENIA"},{"count":1,"reaction":"THROMBOCYTOPENIA"},{"count":1,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":142,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oral steroid medication","Prednisone or equivalent"],"phase":"marketed","status":"active","brandName":"Steroid Drug","genericName":"Steroid Drug","companyName":"Services Hospital, Lahore","companyId":"services-hospital-lahore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Steroids suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus), Allergic reactions and asthma, Adrenal insufficiency.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}